ES2076543T3 - Extracto de kawa-kawa, procedimiento para su preparacion y su utilizacion. - Google Patents

Extracto de kawa-kawa, procedimiento para su preparacion y su utilizacion.

Info

Publication number
ES2076543T3
ES2076543T3 ES91915521T ES91915521T ES2076543T3 ES 2076543 T3 ES2076543 T3 ES 2076543T3 ES 91915521 T ES91915521 T ES 91915521T ES 91915521 T ES91915521 T ES 91915521T ES 2076543 T3 ES2076543 T3 ES 2076543T3
Authority
ES
Spain
Prior art keywords
extract
content
kawa
flavokavin
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91915521T
Other languages
English (en)
Inventor
Klaus-Peter Schwabe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Willmar Schwabe GmbH and Co KG
Original Assignee
Dr Willmar Schwabe GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Willmar Schwabe GmbH and Co KG filed Critical Dr Willmar Schwabe GmbH and Co KG
Application granted granted Critical
Publication of ES2076543T3 publication Critical patent/ES2076543T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

EXTRACTO DE KAVA-KAVA, PROCEDIMIENTO PARA SU PRODUCCION Y SU UTILIZACION. EXTRACTO SECO DE DROGA KAVA CON UN CONTENIDO TOTAL EN KAVALACTONAS DE UN 50% EN PESO COMO MINIMO Y UN CONTENIDO DE FLAVOKAVINA DE UN 0,3% EN PESO COMO MAXIMO. EL EXTRACTO SE CARACTERIZA POR SU BUENA DISOLUBILIDAD EN AGUA Y UNA GRAN BIODISPONIBILIDAD TRAS APLICACION ORAL. PARA PODER SEPARAR LAS KAVALACTONAS Y FLAVOKAVINAS DEL EXTRACTO, SE PROPONE UN PROCEDIMIENTO EN EL QUE EL EXTRACTO BRUTO SE SOMETE A UNA SOLUCION Y SE REDUCE EL CONTENIDO DE FLAVOKAVINAS MEDIANTE PRECIPITACION POR FRIO O POR DISTRIBUCION DE DISOLVENTES, PASANDO LA SOLUCION POSTERIORMENTE CONCENTRADA AL SECADOR. MEDIANTE LA UTILIZACION DEL EXTRACTO SECO SE PRODUCEN MEDICAMENTOS.
ES91915521T 1990-09-12 1991-09-05 Extracto de kawa-kawa, procedimiento para su preparacion y su utilizacion. Expired - Lifetime ES2076543T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4028945A DE4028945A1 (de) 1990-09-12 1990-09-12 Kawa-kawa-extrakt, verfahren zu seiner herstellung und seine verwendung

Publications (1)

Publication Number Publication Date
ES2076543T3 true ES2076543T3 (es) 1995-11-01

Family

ID=6414114

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91915521T Expired - Lifetime ES2076543T3 (es) 1990-09-12 1991-09-05 Extracto de kawa-kawa, procedimiento para su preparacion y su utilizacion.

Country Status (7)

Country Link
EP (1) EP0505519B1 (es)
JP (1) JPH05502457A (es)
AT (1) ATE125707T1 (es)
DE (2) DE4028945A1 (es)
DK (1) DK0505519T3 (es)
ES (1) ES2076543T3 (es)
WO (1) WO1992004036A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4401646A1 (de) * 1994-01-21 1995-07-27 Krewel Werke Gmbh Optimal freisetzende Kava-Extrakte
FR2771002B1 (fr) * 1997-11-17 2000-03-31 Sederma Sa Compositions a usage cosmetique ou dermopharmaceutique contenant un extrait vegetal obtenu a partir des racines de kava piper methysticum
EP0987026A1 (de) * 1998-08-21 2000-03-22 Max Zeller Söhne AG Verfahren zur Herstellung eines Kawa-Kawa-Extraktes
NL1011082C2 (nl) * 1999-01-20 2000-07-21 Danny Van Eijsselsteijn Middel ter verhoging van de erogene gevoeligheid op basis van muira puama.
WO2002007743A2 (de) * 2000-07-26 2002-01-31 Vitaplant Ag Piper methysticum pflanzenextrakt
US6608105B2 (en) 2000-12-18 2003-08-19 Meiji Dairies Corporation TNF-α production inhibitor comprising kavalactone as an active ingredient
WO2005021017A1 (de) * 2003-08-27 2005-03-10 Finzelberg Gmbh & Co. Kg Alkaloid-reduzierter kava-extrakt
CN100456937C (zh) * 2004-09-24 2009-02-04 余内逊 一种咔哇助睡益胃夜豆奶粉制备方法
JP5548916B2 (ja) * 2009-03-04 2014-07-16 公益財団法人岐阜県研究開発財団 カワラクトン誘導体を含有する医薬製剤
CA2827583A1 (en) * 2011-03-01 2012-09-07 Phytomedics Corporation Inc. Methods of processing extracts of a t. wilfordii hook f. plant
CN118948639B (zh) * 2024-07-31 2025-02-11 广州旭帆生物科技有限公司 水溶卡瓦胡椒根茎包裹体粉末及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE197806C (es) *
GB943121A (en) * 1961-05-24 1963-11-27 Thomae Gmbh Dr K Medicines containing lactones from piper methysticum
DE1617812A1 (de) * 1967-06-05 1972-02-17 Spezialchemie Gmbh & Co Verfahren zur Herstellung von endoanaesthetisch wirkenden Loesungen von Kava-Wirkstoffen
DE3303398A1 (de) * 1983-02-02 1984-08-02 Ewald Dr.med.vet. 2060 Bad Oldesloe Karstens Praeparat zur erhaltung und steigerung der geistigen und koerperlichen leistungsfaehigkeit

Also Published As

Publication number Publication date
EP0505519B1 (de) 1995-08-02
DE59106162D1 (de) 1995-09-07
WO1992004036A1 (de) 1992-03-19
EP0505519A1 (de) 1992-09-30
JPH05502457A (ja) 1993-04-28
ATE125707T1 (de) 1995-08-15
DE4028945A1 (de) 1992-03-19
DK0505519T3 (da) 1995-09-18

Similar Documents

Publication Publication Date Title
IT1164550B (it) Prodotto medicinale da somministrare per via orale dotato di azione antiflogistica
IT1207994B (it) Sali idrosulubili di composti adattivita' antiinfiammatoria ed analgesica, loro preparazione ed utilizzo in composizioni farmaceutiche.
SE9203744D0 (sv) Process for the preparation of a pharmaceutical composition selectively lowering the blood lipid level
ES2076543T3 (es) Extracto de kawa-kawa, procedimiento para su preparacion y su utilizacion.
ES2039193T3 (es) Polisacaridos inmunoestimulantes a partir de cultivos de celulas de echinea purpurea (linne) moench y de echinea angustifolia (de vandolle), su procedimiento de preparacion y composiciones farmaceuticas conteniendolos.
DK157061C (da) Fremgangsmaade til fremstilling af et heparinoid med antitrombotisk virkning
SE8702941L (sv) Farmaceutisk, n-acetyl-cysteininnehallande, vattenloslig komposition
ES2060012T5 (es) Polidextrosa modificada y procedimiento para su preparacion.
MX9100246A (es) Preparacion farmaceutica en forma de tabletas o grageas que contienen sulcralfato y procedimiento para su preparacion
KR840002657A (ko) 인터페론 조성물의 제조방법
KR890009868A (ko) 1-메틸-β-옥소-α-(페닐카바모일)-2- 피롤프로피오니트릴의 트로메트아민염
ATE77555T1 (de) Guar-mehl.
GB1259503A (es)
IE782515L (en) Treating diarrhoea
RU96124022A (ru) Способ лечения красного плоского лишая слизистой оболочки полости рта
IE34883L (en) Treatment of marek's disease with ureidodiphenyl sulfone
SE8705035L (sv) Anvaendning av alkylglycerol
IT1213464B (it) Forma farmaceutica per la somministrazione enterica di acido etodolico o di suoi sali, in miscela con eccipienti.
Pearce Aluminium, acid rain and Alzheimer's
KR870010080A (ko) 면역촉진 활성을 갖는 트리펩티드
SU1312777A1 (ru) Способ получения средства, обладающего противосудорожной активностью
IT1204751B (it) Derivati idrosolubili dell'acido 4,5 -difenil- 2 -ossazolpropionico,loro preparazione ed utilizzo in composizioni farmaceutiche
Ricci et al. A study on the frequency of healthy carriers of Yersinia enterocolitica in Brindisi district. Importance of freezing enrichment in the isolation procedures.
GB1354525A (en) Methods for obtaining diuresis in animals
Senczuk et al. Toxicodynamic properties of toluidines. Part V. Methaemoglobin-genic action of toluidines.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 505519

Country of ref document: ES